CY1123697T1 - Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη - Google Patents

Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη

Info

Publication number
CY1123697T1
CY1123697T1 CY20201101133T CY201101133T CY1123697T1 CY 1123697 T1 CY1123697 T1 CY 1123697T1 CY 20201101133 T CY20201101133 T CY 20201101133T CY 201101133 T CY201101133 T CY 201101133T CY 1123697 T1 CY1123697 T1 CY 1123697T1
Authority
CY
Cyprus
Prior art keywords
amd
aflivercept
treatment
aav2 variant
aav2
Prior art date
Application number
CY20201101133T
Other languages
English (en)
Inventor
Mark Blumenkranz
Mehdi Gasmi
Original Assignee
Adverum Biotechnologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies, Inc. filed Critical Adverum Biotechnologies, Inc.
Publication of CY1123697T1 publication Critical patent/CY1123697T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Anesthesiology (AREA)

Abstract

Η παρούσα αποκάλυψη παρέχει φαρμακευτικές συνθέσεις και μεθόδους αυτών για τη θεραπεία της ηλικιακής εκφύλισης της ωχράς κηλίδας (AMD) σε ένα υποκείμενο δια χορήγησης εντός του υαλοειδούς μιας φαρμακευτικής σύνθεσης προσαρμοσμένης για γονιδιακή θεραπεία, που περιλαμβάνει έναν φορέα που έχει μία αλληλουχία νουκλεϊκών οξέων που κωδικοποιεί αφλιβερσέπτη.
CY20201101133T 2016-06-16 2020-11-30 Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη CY1123697T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351234P 2016-06-16 2016-06-16
PCT/US2017/038003 WO2017218974A2 (en) 2016-06-16 2017-06-16 Treatment of amd using aav2 variant with aflibercept

Publications (1)

Publication Number Publication Date
CY1123697T1 true CY1123697T1 (el) 2022-03-24

Family

ID=60663653

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101133T CY1123697T1 (el) 2016-06-16 2020-11-30 Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη

Country Status (22)

Country Link
US (2) US20190151409A1 (el)
EP (2) EP3795181A1 (el)
JP (3) JP6814822B2 (el)
KR (2) KR102218265B1 (el)
CN (2) CN109641065A (el)
AU (2) AU2017286673B2 (el)
BR (1) BR112018076124A2 (el)
CA (1) CA3027737A1 (el)
CY (1) CY1123697T1 (el)
DK (1) DK3471780T3 (el)
ES (1) ES2840059T3 (el)
HR (1) HRP20201842T1 (el)
HU (1) HUE051953T2 (el)
IL (2) IL263686B (el)
LT (1) LT3471780T (el)
MX (2) MX2018015512A (el)
PT (1) PT3471780T (el)
RS (1) RS61311B1 (el)
SG (1) SG11201811232XA (el)
SI (1) SI3471780T1 (el)
WO (1) WO2017218974A2 (el)
ZA (1) ZA201808538B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015231439B2 (en) 2014-03-17 2019-11-14 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
SG11201707063TA (en) 2015-03-02 2017-09-28 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
MX2019011040A (es) 2017-03-17 2020-01-20 Adverum Biotechnologies Inc Composiciones y metodos para potenciar la expresion genica.
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
SG11202004545XA (en) * 2017-11-27 2020-06-29 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and use for inhibiting angiogenesis
WO2019126329A1 (en) 2017-12-19 2019-06-27 Akouos Llc Aav-mediated delivery of therapeutic antibodies to the inner ear
US20210154270A1 (en) * 2018-04-12 2021-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-aging compositions and methods of use
WO2020180951A1 (en) * 2019-03-04 2020-09-10 Adverum Biotechnologies, Inc. Sequential intravitreal administration of aav gene therapy to contralateral eyes
BR112022003206A2 (pt) * 2019-09-11 2022-08-16 Adverum Biotechnologies Inc Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte
JP2022547541A (ja) * 2019-09-11 2022-11-14 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法
TWI819268B (zh) 2020-01-16 2023-10-21 詹姆斯 Ｗ 希爾 藉由基因轉導改變眼睛顏色
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
JP2021049374A (ja) * 2020-12-09 2021-04-01 株式会社三洋物産 遊技機
JP2024515459A (ja) * 2021-04-27 2024-04-10 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用する眼疾患の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2699270B1 (en) * 2011-04-22 2017-06-21 The Regents of The University of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2753135T3 (es) * 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
CA3107182A1 (en) * 2013-07-12 2015-01-15 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
EP3057990B1 (en) * 2013-10-18 2019-09-04 Regeneron Pharmaceuticals, Inc. Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
SG11201707063TA (en) * 2015-03-02 2017-09-28 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones

Also Published As

Publication number Publication date
ES2840059T3 (es) 2021-07-06
DK3471780T3 (da) 2020-11-23
CA3027737A1 (en) 2017-12-21
WO2017218974A2 (en) 2017-12-21
AU2021225178A1 (en) 2021-09-30
AU2017286673A1 (en) 2019-01-31
IL263686A (en) 2019-01-31
KR20190037228A (ko) 2019-04-05
MX2022004786A (es) 2022-05-16
RS61311B1 (sr) 2021-02-26
US20190151409A1 (en) 2019-05-23
HUE051953T2 (hu) 2021-04-28
SG11201811232XA (en) 2019-01-30
EP3795181A1 (en) 2021-03-24
KR20210021113A (ko) 2021-02-24
EP3471780B1 (en) 2020-10-28
US20220265740A1 (en) 2022-08-25
BR112018076124A2 (pt) 2019-03-26
WO2017218974A3 (en) 2018-01-25
PT3471780T (pt) 2020-12-17
ZA201808538B (en) 2021-04-28
IL279919A (en) 2021-03-01
LT3471780T (lt) 2021-01-25
CN117531025A (zh) 2024-02-09
SI3471780T1 (sl) 2021-03-31
HRP20201842T1 (hr) 2021-04-16
EP3471780A4 (en) 2019-04-24
JP2019521990A (ja) 2019-08-08
JP6814822B2 (ja) 2021-01-20
JP2020203941A (ja) 2020-12-24
CN109641065A (zh) 2019-04-16
MX2018015512A (es) 2019-04-24
KR102218265B1 (ko) 2021-02-25
JP2022137244A (ja) 2022-09-21
IL263686B (en) 2021-02-28
AU2017286673B2 (en) 2021-06-24
EP3471780A2 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
CY1123697T1 (el) Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1123642T1 (el) Αντισωματα enanti-pd-1
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
CY1123274T1 (el) Αντισωματα εναντι-οχ40 και χρησεις αυτων
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
CY1124588T1 (el) Γενετικο κατασκευασμα
WO2015109124A3 (en) Immunomodulatory agents
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
PH12019500209A1 (en) Methods and compositions for gene expression in plants
ZA201506093B (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
AR099837A1 (es) Terapia génica para la retinitis pigmentaria
CY1123947T1 (el) Βελτιστοποιημενος υποκινητης rpe65 και βελτιστοποιημενες κωδικοποιητικες αλληλουχιες
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.